----

**SECURITIES      AND EXCHANGE COMMISSION**

**Washington,      D.C. 20549 **

**FORM      10-QSB**

**A      J&J PHARMA CORPORATION**

|  NEVADA                                                                        |  86-1024812                                    |
|-------------------------------------------------------------------------------------|-----------------------------------------------------|
|  (State                or other jurisdiction of incorporation or organization) | (I.R.S.                Employer Identification No.) |

----

**A      J&J PHARMA CORPORATION**

**(A      DEVELOPMENT STAGE COMPANY)**

|   TABLE                OF CONTENTS |
|----------------------------------------------|
|                                         |   |   |   |   |   |   |   |   |
|                                         |   |   |   |   |   |   |   | Page |
| Part                I                        | Financial                Information | 3 |
|                                         |   |   |   |   |   |   |   |   |
| Item                1.                       | Financial                Statements: | 3 |
|                                         |   |   |   |   |   |   |   |   |
|                                         | Condensed                Balance Sheets September                30, 2006 (unaudited) and December 31, 2005 |  3 |
|                                         |   |   |
|                                         | Unaudited                  Condensed Statements of Operations for the three                  and nine months ended September 30, 2006 and 2005, and cumulative                  from                  inception on July 16,1998 through September 30,                  2006 |  4 |
|                                         |   |   |
|                                         | Unaudited                  Condensed Statements of Cash Flows for the nine                  months ended September 30, 2006 and 2005, and cumulative from inception                  on                  July 16, 1998 through September 30, 2006 |  5 |
|                                         |   |   |
|                                         | Statement                  of Stockholders' Equity (Deficit) for the period from July                  16,1998 to September 30, 2006 (unaudited) |  6 |
|                                         |   |   |
|                                         |  Notes                to Financial Statements (unaudited) |  7 |
|                                         |   |   |
| Item                2.                       |  Plan                of operation |  7 |
|                                         |   |   |
|  Part                II                 |  Other                Information |  7 |
|                                         |   |   |
|  Item                1.                 |  Legal                Proceedings |  7 |
|                                         |   |   |
|  Item                2.                 |  Changes                in Securities |  7 |
|                                         |   |   |
|  Item                6.                 |  Exhibits                and Reports on Form 8-K |  7 |
|                                         |   |   |
|                                         |  Signatures |  7 |
|                                         |   |   |
|                                         |  Certifications |  8                - 10 |

----

| **AJ                  & J PHARMA CORPORATION**                                                                                            |
|-----------------------------------------------------------------------------------------------------------------------------------------------|
| **(A                  DEVELOPMENT STAGE ENTERPRISE)**                                                                                         |
| **CONDENSED                  BALANCE SHEETS**                                                                                                 |
|                                                                                                                                          |   |   |   |   |   |   |   |
|                                                                                                                                          |   |   |   |   |   |   |   |
|                                                                                                                                          |   |   |   |   |   |   |   |
|                                                                                                                                          |   |   |   |   |   |   |   |
|                                                                                                                                          |   |   | September                  30,  |   |   | December                  31, |   |
|                                                                                                                                          |   |   | 2006 |   |   | 2005 |   |
|                                                                                                                                          |   |   | (unaudited)  |   |   |   |   |
| **ASSETS**                                                                                                                                    |   |   |   |   |   |   |   |
|                                                                                                                                          |   |   |   |   |   |   |   |
|  CURRENT                  ASSETS                                                                                                         |   | $ | - |   | $ | - |   |
|                                                                                                                                          |   |   |   |   |   |   |   |
|                                                                                                                                          |   |   |   |   |   |   |   |
|                                                                                                                                          |   |   |   |   |   |   |   |
|                                                                                                                                          |   |   |   |   |   |   |   |
| **LIABILITIES                  AND STOCKHOLDERS' EQUITY (DEFICIT)**                                                                           |   |   |   |   |   |   |   |
|                                                                                                                                          |   |   |   |   |   |   |   |
|                                                                                                                                          |   |   |   |   |   |   |   |
| CURRENT                  LIABILITIES                                                                                                          |   |   |   |   |   |   |   |
|                                                                                                                                          |   |   |   |   |   |   |   |
|     Accounts                  payable, Officers                                                                           |   | $ | 38,675 |   | $ | 33,128 |   |
|                                                                                                                                          |   |   |   |   |   |   |   |
|     Total                  Current Liabilities                                                                            |   |   | 38,675 |   |   | 33,128 |   |
|                                                                                                                                          |   |   |   |   |   |   |   |
|                                                                                                                                          |   |   |   |   |   |   |   |
| STOCKHOLDERS'                  EQUITY (DEFICIT)                                                                                               |   |   |   |   |   |   |   |
|                                                                                                                                          |   |   |   |   |   |   |   |
| Common                    stock, par value $.001, 25,000,000 shares authorized, 1,000,000                    issued and outstanding |   |   | 1,000 |   |   | 1,000 |   |
| Paid                  in capital                                                                                                              |   |   | 1,800 |   |   | 1,800 |   |
| (Deficit)                  accumulated during the development stage                                                                           |   |   | (41,475 | ) |   | (35,928 | ) |
|                                                                                                                                          |   |   |   |   |   |   |   |
|                                                                                                                                          |   |   |   |   |   |   |   |
| Total                  Stockholders' Equity (Deficit)                                                                                         |   |   | (38,675 | ) |   | (33,128 | ) |
|                                                                                                                                          |   |   |   |   |   |   |   |
|                                                                                                                                               |   | $ | -  |   | $ | - |   |
|                                                                                                                                          |   |   |   |   |   |   |   |
|                                                                                                                                          |   |   |   |   |   |   |   |
| SEE                  ACCOMPANYING NOTES TO FINANCIAL                  STATEMENTS                                                              |

----

| **AJ                  & J PHARMA CORPORATION**                               |
|----------------------------------------------------------------------------------|
| **(A                  DEVELOPMENT STAGE ENTERPRISE)**                            |
| **CONDENSED                  STATEMENTS OF OPERATIONS**                          |
| **(unaudited)**                                                                  |
|                                                                             |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|                                                                             |   |   |   |   |   |   |   |   |   |   |   |   |   |   | Cumulative  |   |
|                                                                             |   |   |   |   |   |   |   |   |   |   |   |   |   |   | from  |   |
|                                                                             |   |   |   |   |   |   |   |   |   |   |   |   |   |   | July                  16,  |   |
|                                                                             |   |   |   |   |   |   |   |   |   |   |   |   |   |   | 1998 |   |
|                                                                             |   | Three                  Months Ended  | Nine                  Months Ended |   | (Inception) |   |
|                                                                             |   | September                  30,  | September                  30, |   | to |   |
|                                                                             |   |   | 2006 |   |   | 2005 |   |   | 2006 |   |   | 2005 |   |   | September                  30, 2006 |   |
|                                                                             |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| REVENUES                                                                         |   | $ | - |   | $ | - |   | $ | - |   | $ | - |   | $ | - |   |
|                                                                             |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| EXPENSES                                                                         |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|     General                  and administrative              |   |   | 1,487 |   |   | 1,416 |   |   | 5,547 |   |   | 5,162 |   |   | 41,475 |   |
|                                                                             |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|     Total                  expenses                          |   |   | 1,487 |   |   | 1,416 |   |   | 5,547 |   |   | 5,162 |   |   | 41,475 |   |
|                                                                             |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| NET                  (LOSS)                                                      |   | $ | (1,487 | ) | $ | (1,416 | ) | $ | (5,547 | ) | $ | (5,162 | ) | $ | (41,475 | ) |
|                                                                             |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| NET                  (LOSS) PER SHARE                                            |   |   | * |   |   | * |   |   | * |   |   | * |   |   |   |   |
|                                                                             |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| WEIGHTED                  AVERAGE NUMBER OF                                      |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|  COMMON                  SHARES OUTSTANDING                                 |   |   | 1,000,000 |   |   | 1,000,000 |   |   | 1,000,000 |   |   | 1,000,000 |   |   |   |   |
|                                                                             |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|                                                                             |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| *                  less than $ (0.01) per share                                  |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|                                                                             |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|                                                                             |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|                                                                             |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| SEE                  ACCOMPANYING NOTES TO FINANCIAL                  STATEMENTS |

----

| **AJ                  & J PHARMA CORPORATION**                                           |
|----------------------------------------------------------------------------------------------|
| **(A                  DEVELOPMENT STAGE ENTERPRISE)**                                        |
| **CONDENSED                  STATEMENTS OF CASH FLOWS**                                      |
| **(unaudited)**                                                                              |
|                                                                                         |   |   |   |   |   |   |   |   |   |   |
|                                                                                         |   |   |   |   |   |   |   |   |   |   |
|                                                                                         |   |   |   |   |   |   |   |   | Cumulative  |   |
|                                                                                         |   |   |   |   |   |   |   |   | from  |   |
|                                                                                         |   |   |   |   |   |   |   |   | July                  16,  |   |
|                                                                                         |   |   |   |   |   |   |   |   | 1998 |   |
|                                                                                         |   |   | Nine                  Months Ended  |   |   | (Inception) |   |
|                                                                                         |   |   | September                  30,   |   |   | to |   |
|                                                                                         |   |   | 2006 |   |   | 2005 |   |   | September                  30, 2006 |   |
|                                                                                         |   |   |   |   |   |   |   |   |   |   |
| **OPERATING                  ACTIVITIES**                                                    |   |   |   |   |   |   |   |   |   |   |
|     Net                  (loss) from operations                          |   | $ | (5,547 | ) | $ | (5,162 | ) | $ | (41,475 | ) |
|                                                                                         |   |   |   |   |   |   |   |   |   |   |
| **NET                  CASH (USED BY) OPERATING ACTIVITIES**                                 |   |   | (5,547 | ) |   | (5,162 | ) |   | (41,475 | ) |
|                                                                                         |   |   |   |   |   |   |   |   |   |   |
| **FINANCING                  ACTIVITIES**                                                    |   |   |   |   |   |   |   |   |   |   |
|     Shareholder                  advances                                |   |   | 5,547 |   |   | 5,162 |   |   | 38,675 |   |
|     Proceeds                  from                  sale of common stock |   |   |   |   |   |   |   |   | 2,800 |   |
|                                                                                         |   |   |   |   |   |   |   |   |   |   |
| **NET                  CASH PROVIDED BY FINANCING ACTIVITIES**                               |   |   | 5,547 |   |   | 5,162 |   |   | 41,475 |   |
|                                                                                         |   |   |   |   |   |   |   |   |   |   |
| **NET                  INCREASE IN CASH**                                                    |   |   | (0 | ) |   | 0 |   |   | - |   |
|                                                                                         |   |   |   |   |   |   |   |   |   |   |
| **CASH,                  BEGINNING OF PERIOD**                                               |   |   |   |   |   |   |   |   | - |   |
|                                                                                         |   |   |   |   |   |   |   |   |   |   |
| **CASH,                  END OF PERIOD**                                                     |   | $ | (0 | ) | $ | 0 |   | $ | - |   |
|                                                                                         |   |   |   |   |   |   |   |   |   |   |
|                                                                                         |   |   |   |   |   |   |   |   |   |   |
|  SEE                  ACCOMPANYING NOTES TO FINANCIAL                  STATEMENTS       |

----

| **AJ                    & J PHARMA CORPORATION**                                     |
|------------------------------------------------------------------------------------------|
| **(A                    DEVELOPMENT STAGE ENTERPRISE)**                                  |
| **STATEMENT                    OF STOCKHOLDERS' EQUITY (DEFICIT)**                       |
|                                                                                     |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|                                                                                     |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|                                                                                     |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|                                                                                     |   |   |   |   |   |   |   |   |   |   |   | **(Deficit)**  |   |   |   |   |
|                                                                                     |   |   |   |   |   |   |   |   |   |   |   | **Accumulated**  |   |   |   |   |
|                                                                                     |   |   |   |   |   |   |   |   |   |   |   | **During                    the**  |   |   |   |   |
|                                                                                     |   |   | **Common                    Stock**  |   |   | **Paid-in** |   |   | **Development** |   |   |   |   |
|                                                                                     |   |   | **Shares**  |   |   | **Amount** |   |   | **Capital** |   |   | **Stage** |   |   | **Total** |   |
|                                                                                     |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| **Balances,                    at inception**                                            |   |   | - |   | $ | - |   | $ | - |   | $ | - |   | $ | - |   |
| July                    16, 1998:                                                        |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Proceeds                      from sale of common stock at $.01 per share           |   |   | 200,000 |   |   | 200 |   |   | 1,800 |   |   |   |   |   | 2,000 |   |
| Proceeds                      from sale of common stock at par value $.001          |   |   | 800,000 |   |   | 800 |   |   |   |   |   |   |   |   | 800 |   |
|     Net                    (loss) for the period                     |   |   |    |   |   |    |   |   |    |   |   | (2,385 | ) |   | (2,385 | ) |
|                                                                                     |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| **Balances,                    December 31, 1998**                                       |   |   | 1,000,000 |   |   | 1,000 |   |   | 1,800 |   |   | (2,385 | ) |   | 415 |   |
|     Net                    (loss) for the year                       |   |   |    |   |   |    |   |   |    |   |   | (2,985 | ) |   | (2,985 | ) |
|                                                                                     |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| **Balances,                    December 31, 1999**                                       |   |   | 1,000,000 |   |   | 1,000 |   |   | 1,800 |   |   | (5,370 | ) |   | (2,570 | ) |
|     Net                    (loss) for the year                       |   |   |    |   |   |    |   |   |    |   |   | (2,985 | ) |   | (2,985 | ) |
|                                                                                     |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| **Balances,                    December 31, 2000**                                       |   |   | 1,000,000 |   |   | 1,000 |   |   | 1,800 |   |   | (8,355 | ) |   | (5,555 | ) |
|     Net                    (loss) for the year                       |   |   |    |   |   |    |   |   |    |   |   | (5,685 | ) |   | (5,685 | ) |
|                                                                                     |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| **Balances,                    December 31, 2001**                                       |   |   | 1,000,000 |   |   | 1,000 |   |   | 1,800 |   |   | (14,040 | ) |   | (11,240 | ) |
|     Net                    (loss) for the year                       |   |   |    |   |   |    |   |   |    |   |   | (4,335 | ) |   | (4,335 | ) |
|                                                                                     |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| **Balances,                    December 31, 2002**                                       |   |   | 1,000,000 |   |   | 1,000 |   |   | 1,800 |   |   | (18,375 | ) |   | (15,575 | ) |
| Net                    (loss) for the year                                               |   |   |    |   |   |    |   |   |    |   |   | (4,358 | ) |   | (4,358 | ) |
|                                                                                     |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| **Balances,                    December 31, 2003**                                       |   |   | 1,000,000 |   |   | 1,000 |   |   | 1,800 |   |   | (22,733 | ) |   | (19,933 | ) |
|     Net                    (loss) for the year                       |   |   |    |   |   |    |   |   |    |   |   | (6,605 | ) |   | (6,605 | ) |
|                                                                                     |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| **Balances,                    December 31, 2004**                                       |   |   | 1,000,000 |   |   | 1,000 |   |   | 1,800 |   |   | (29,338 | ) |   | (26,538 | ) |
|                                                                                     |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|     Net                    (loss) for the year                       |   |   |    |   |   |    |   |   |    |   |   | (6,590 | ) |   | (6,590 | ) |
|                                                                                     |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| **Balances,                    December 31, 2005**                                       |   |   | 1,000,000 |   |   | 1,000 |   |   | 1,800 |   |   | (35,928 | ) |   | (33,128 | ) |
| **(unaudited)**                                                                          |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|     Net                    (loss) for the period                     |   |   |    |   |   |    |   |   |    |   |   | (5,547 | ) |   | (5,547 | ) |
|                                                                                     |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| **Balances,                    September 30, 2006 (unaudited)**                          |   |   | 1,000,000 |   | $ | 1,000 |   | $ | 1,800 |   | $ | (41,475 | ) | $ | (38,675 | ) |
|                                                                                     |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|                                                                                     |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| **SEE                    ACCOMPANYING NOTES TO FINANCIAL                    STATEMENTS** |

----

| 31.1 | Certificate                of CEO as Required by Rule 13a-14(a)/15d-14                |
|------|---------------------------------------------------------------------------------------|
| 31.2 | Certificate                of CFO as Required by Rule                13a-14(a)/15d-14 |

| 32 | Certificate                of CEO & CFO as Required by Rule Rule 13a-14(b) and Rule 15d-14(b) (17                CFR 240.15d-14(b)) and Section 1350 of Chapter 63 of Title 18 of                the                United States Code |
|----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

----

| (a) | Designed                such disclosure controls and procedures, or caused such disclosure                controls and procedures to be designed under our supervision, to                ensure                that material information relating to the small business issuer,                including                its consolidated subsidiaries, is made known to us by others within                those                entities, particularly during the period in which this report is                being                prepared; |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (b)  | Designed                such internal control over financial reporting, or caused such internal                control over financial reporting to be designed under our supervision,                to                provide reasonable assurance regarding the reliability of financial                reporting and the preparation of financial statements for external                purposes in accordance with generally accepted accounting                principles; |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (c)  | Evaluated                the effectiveness of the small business issuer's disclosure controls                and                procedures and presented in this report our conclusions about the                effectiveness of the disclosure controls and procedures, as of the                end of                the period covered by this report based on such evaluation;                and |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (d)  | Disclosed                in this report any change in the small business issuer's internal                control                over financial reporting that occurred during the small business                issuer's                most recent fiscal quarter (the small business issuer's fourth fiscal                quarter in the case of an annual report) that has materially affected,                or                is reasonably likely to materially affect, the small business issuer's                internal control over financial reporting;                and |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (a)  | All                significant deficiencies and material weaknesses in the design or                operation of internal control over financial reporting which are                reasonably likely to adversely affect the small business issuer's                ability                to record, process, summarize and report financial information;                and |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (b)  | Any                fraud, whether or not material, that involves management or other                employees who have a significant role in the small business issuer's                internal control over financial                reporting. |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

----

| (a) | Designed                such disclosure controls and procedures, or caused such disclosure                controls and procedures to be designed under our supervision, to                ensure                that material information relating to the small business issuer,                including                its consolidated subsidiaries, is made known to us by others within                those                entities, particularly during the period in which this report is                being                prepared; |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (b)  | Designed                such internal control over financial reporting, or caused such internal                control over financial reporting to be designed under our supervision,                to                provide reasonable assurance regarding the reliability of financial                reporting and the preparation of financial statements for external                purposes in accordance with generally accepted accounting                principles; |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (c)  | Evaluated                the effectiveness of the small business issuer's disclosure controls                and                procedures and presented in this report our conclusions about the                effectiveness of the disclosure controls and procedures, as of the                end of                the period covered by this report based on such evaluation;                and |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (d)  | Disclosed                in this report any change in the small business issuer's internal                control                over financial reporting that occurred during the small business                issuer's                most recent fiscal quarter (the small business issuer's fourth fiscal                quarter in the case of an annual report) that has materially affected,                or                is reasonably likely to materially affect, the small business issuer's                internal control over financial reporting;                and |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (a)  | All                significant deficiencies and material weaknesses in the design or                operation of internal control over financial reporting which are                reasonably likely to adversely affect the small business issuer's                ability                to record, process, summarize and report financial information;                and |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (b)  | Any                fraud, whether or not material, that involves management or other                employees who have a significant role in the small business issuer's                internal control over financial                reporting. |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

----

----